192 related articles for article (PubMed ID: 32241693)
1. Survival outcomes and practice trends for off-label use of adjuvant targeted therapy in high-risk locoregional renal cell carcinoma.
Chakiryan NH; Acevedo AM; Garzotto MA; Chen Y; Liu JJ; Isharwal S; Amling CL; Kopp RP
Urol Oncol; 2020 Jun; 38(6):604.e1-604.e7. PubMed ID: 32241693
[TBL] [Abstract][Full Text] [Related]
2. Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy.
Bandini M; Smith A; Zaffuto E; Pompe RS; Marchioni M; Capitanio U; Chun FK; Kapoor AB; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
World J Urol; 2018 Jan; 36(1):51-57. PubMed ID: 29022072
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
[TBL] [Abstract][Full Text] [Related]
4. Oncological outcomes of minimally invasive partial versus minimally invasive radical nephrectomy for cT1-2/N0/M0 clear cell renal cell carcinoma: a propensity score-matched analysis.
Simone G; Tuderti G; Anceschi U; Papalia R; Ferriero M; Misuraca L; Minisola F; Mastroianni R; Costantini M; Guaglianone S; Sentinelli S; Gallucci M
World J Urol; 2017 May; 35(5):789-794. PubMed ID: 27578234
[TBL] [Abstract][Full Text] [Related]
5. The natural history of renal cell carcinoma with isolated lymph node metastases following surgical resection from 2006 to 2013.
Golijanin B; Pereira J; Mueller-Leonhard C; Golijanin D; Amin A; Mega A; Boorjian SA; Thompson RH; Leibovich BC; Gershman B
Urol Oncol; 2019 Dec; 37(12):932-940. PubMed ID: 31570248
[TBL] [Abstract][Full Text] [Related]
6. A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality.
Palumbo C; Mazzone E; Mistretta FA; Knipper S; Perrotte P; Shariat SF; Saad F; Kapoor A; Lattouf JB; Simeone C; Briganti A; Antonelli A; Karakiewicz PI
Clin Genitourin Cancer; 2020 Aug; 18(4):314-321.e1. PubMed ID: 32482565
[TBL] [Abstract][Full Text] [Related]
7. A prospective study of pediatric and adolescent renal cell carcinoma: A report from the Children's Oncology Group AREN0321 study.
Geller JI; Cost NG; Chi YY; Tornwall B; Cajaiba M; Perlman EJ; Kim Y; Mullen EA; Glick RD; Khanna G; Daw NC; Ehrlich P; Fernandez CV; Dome JS;
Cancer; 2020 Dec; 126(23):5156-5164. PubMed ID: 32926409
[TBL] [Abstract][Full Text] [Related]
8. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
[TBL] [Abstract][Full Text] [Related]
9. Does the Unexpected Presence of Non-organ-confined Disease at Final Pathology Undermine Cancer Control in Patients with Clinical T1N0M0 Renal Cell Carcinoma Who Underwent Partial Nephrectomy?
Capitanio U; Stewart GD; Klatte T; Akdogan B; Roscigno M; Marszalek M; Dell'Oglio P; Zaffuto E; Rodriguez Faba O; Salagierski M; Lingard J; Carini M; Ouzaid I; Mir MC; Montorsi F; Da Pozzo LF; Stief C; Minervini A; Brookman-May SD
Eur Urol Focus; 2018 Dec; 4(6):972-977. PubMed ID: 28753867
[TBL] [Abstract][Full Text] [Related]
10. Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study.
Hanna N; Sun M; Meyer CP; Nguyen PL; Pal SK; Chang SL; de Velasco G; Trinh QD; Choueiri TK
J Clin Oncol; 2016 Sep; 34(27):3267-75. PubMed ID: 27325852
[TBL] [Abstract][Full Text] [Related]
11. Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage Ib-II renal masses: An analysis of the national cancer data base.
Ristau BT; Handorf EA; Cahn DB; Kutikov A; Uzzo RG; Smaldone MC
Cancer; 2018 Oct; 124(19):3839-3848. PubMed ID: 30207380
[TBL] [Abstract][Full Text] [Related]
12. Referral and adjuvant treatment patterns after nephrectomy in high-risk locoregional renal cell carcinoma.
Dzimitrowicz H; Esterberg E; Miles L; Zanotti G; Borham A; Harrison MR
Cancer Med; 2021 Dec; 10(24):8891-8898. PubMed ID: 34751002
[TBL] [Abstract][Full Text] [Related]
13. Oncologic outcomes of patients with positive surgical margin after partial nephrectomy: a 25-year single institution experience.
Petros FG; Metcalfe MJ; Yu KJ; Keskin SK; Fellman BM; Chang CM; Gu C; Tamboli P; Matin SF; Karam JA; Wood CG
World J Urol; 2018 Jul; 36(7):1093-1101. PubMed ID: 29488096
[TBL] [Abstract][Full Text] [Related]
14. Treatment trends, determinants, and survival of partial and radical nephrectomy for stage I renal cell carcinoma: results from the National Cancer Data Base, 2004-2013.
Plante K; Stewart TM; Wang D; Bratslavsky G; Formica M
Int Urol Nephrol; 2017 Aug; 49(8):1375-1381. PubMed ID: 28550475
[TBL] [Abstract][Full Text] [Related]
15. Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach.
Badalato GM; Kates M; Wisnivesky JP; Choudhury AR; McKiernan JM
BJU Int; 2012 May; 109(10):1457-62. PubMed ID: 21933334
[TBL] [Abstract][Full Text] [Related]
16. Can partial nephrectomy provide equal oncological efficiency and safety compared with radical nephrectomy in patients with renal cell carcinoma (≥4cm)? A propensity score-matched study.
Lee H; Oh JJ; Byun SS; Jeong CW; Kwak C; Jeong BC; Jeon SS; Lee HM; Choi HY; Seo SI
Urol Oncol; 2017 Jun; 35(6):379-385. PubMed ID: 28284894
[TBL] [Abstract][Full Text] [Related]
17. ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma.
Kaffenberger SD; Morgan TM; Stratton KL; Boachie AM; Barocas DA; Chang SS; Cookson MS; Herrell SD; Smith JA; Clark PE
BJU Int; 2012 Dec; 110(11 Pt B):E641-6. PubMed ID: 22958439
[TBL] [Abstract][Full Text] [Related]
18. [Adjuvant autologous tumour cell vaccination in patients with renal cell carcinoma. Overall survival analysis with a follow-up period in excess of more than 10 years].
May M; Kendel F; Hoschke B; Gilfrich C; Kiessig S; Pflanz S; Seidel M; Brookman-Amissah S
Urologe A; 2009 Sep; 48(9):1075-83. PubMed ID: 19562320
[TBL] [Abstract][Full Text] [Related]
19. Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain RK; Chahoud J; Spiess PE; Sexton W; Gilbert SM; Manley BJ
JAMA Netw Open; 2021 May; 4(5):e2111329. PubMed ID: 34032854
[TBL] [Abstract][Full Text] [Related]
20. Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial.
Ristau BT; Manola J; Haas NB; Heng DYC; Messing EM; Wood CG; Kane CJ; DiPaola RS; Uzzo RG
J Urol; 2018 Jan; 199(1):53-59. PubMed ID: 28728992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
